ConductScience.org, home

Paper41344992

TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

Sponheimer M and 28 others. J Immunother Cancer, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. Papers, record 41344992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41344992

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.
PubMed
Journal
J Immunother Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-12-10
PubMed

Authors29

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sponheimer MMonikahttps://orcid.org/0009-0005-2568-3893
2White KKieron
3Ulrich MMichelle
4Kazerani MMaryamhttps://orcid.org/0000-0002-5803-4807
5Maiser AAndreas
6Tyborski ETEmil Thore
7Rappa GPGiulia Petra
8Richter DDaniel
9Briem EEva
10Hänel GGerulf
11Philipp NNora
12Nixdorf DDanielhttps://orcid.org/0000-0003-1612-9952
13Rohrbacher LLisa
14Marcinek AAnetta
15Linder AAndreas
16Kuhl NNiklas
17Piseddu IIgnazio
18Straub TTobias
19Harz HHartmann
20Wichmann CChristian

Source PubMed

See all 29 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
CD27 LigandMajor topic
Tumor Necrosis Factor-alphaMajor topic
Antibody-Dependent Cell CytotoxicityMajor topic
Interferon-gammaMajor topic
Humans
Animals
Mice
Mice, SCID
Female
Male
Cell Line, Tumor
Xenograft Model Antitumor Assays
Killer Cells, Natural

Source PubMed

Download CSV of topics

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138943249NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody.Mol Ther2024https://conductscience.org/library/papers/38943249PubMed
217538161
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
J Clin Oncol2007https://conductscience.org/library/papers/17538161PubMed
330024784CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.J Clin Oncol2018https://conductscience.org/library/papers/30024784PubMed
430275109Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.Blood2018https://conductscience.org/library/papers/30275109PubMed
531826340Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.N Engl J Med2019https://conductscience.org/library/papers/31826340PubMed
628031480CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.J Exp Med2017https://conductscience.org/library/papers/28031480PubMed
733052757ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.J Clin Oncol2021https://conductscience.org/library/papers/33052757PubMed
832601337Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.Nat Med2020https://conductscience.org/library/papers/32601337PubMed
936416736Allogeneic natural killer cell therapy.Blood2023https://conductscience.org/library/papers/36416736PubMed
1030555165Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.Leukemia2019https://conductscience.org/library/papers/30555165PubMed
1129707140A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.Oncotarget2018https://conductscience.org/library/papers/29707140PubMed
1221841316Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.J Clin Invest2011https://conductscience.org/library/papers/21841316PubMed
1334991665The CD70-CD27 axis in oncology: the new kids on the block.J Exp Clin Cancer Res2022https://conductscience.org/library/papers/34991665PubMed
1424300852CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Blood2014https://conductscience.org/library/papers/24300852PubMed
1519062317Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.Immunity2008https://conductscience.org/library/papers/19062317PubMed
1622863621Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.J Clin Invest2012https://conductscience.org/library/papers/22863621PubMed
1736758420Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.Gynecol Oncol2023https://conductscience.org/library/papers/36758420PubMed
1822031859IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.Blood2011https://conductscience.org/library/papers/22031859PubMed
1926942060Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.Oncoimmunology2016https://conductscience.org/library/papers/26942060PubMed
2025186908OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines.Genome Res2014https://conductscience.org/library/papers/25186908PubMed

See all 59 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42398968Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.J Immunother Cancer2026https://conductscience.org/library/papers/42398968PubMed
42035126Bispecific CD37-Siglec6 CAR‑T cells exhibit enhanced anti‑leukemic activity and reduced exhaustion in acute myeloid leukemia xenograft models.J Transl Med2026https://conductscience.org/library/papers/42035126PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41344992

GET https://conductscience.org/api/papers/v1/41344992/authors?page=2